Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A defibrillator placed outside the blood vessels is showing strong real-world results. The Aurora EV-ICD successfully terminated 100% of spontaneous dangerous heart rhythm episodes with shock therapy over 1 year, across nearly 800 patients in 23 countries. With a major complication-free rate of 89.1% and no device-related deaths, it's emerging as a compelling option for sudden cardiac death prevention.
A new type of implantable defibrillator — one placed outside the blood vessels rather than inside them — is delivering impressive results in the real world. The Aurora extravascular ICD (EV-ICD), which uses a substernal lead and a built-in discriminator to reduce unnecessary shocks, was evaluated in the global Enlighten registry across 23 countries, enrolling 787 patients between September 2023 and March 2025.
The device performed reliably across the board: lead placement succeeded in 99.2% of patients, and every discrete spontaneous episode of ventricular tachycardia or ventricular fibrillation was successfully terminated. Antitachycardia pacing also helped 22 patients avoid shocks altogether — a meaningful quality-of-life win.
By the Numbers:
Why it matters: For patients who need protection from sudden cardiac death but don't require pacemaker support for slow heart rates, the EV-ICD offers a less invasive, blood vessel-sparing alternative — with real-world data now backing up its safety and effectiveness.
